Xiaoyun Zhou, Jiawei Shou, Jin Sheng, Chunwei Xu, Shengxiang Ren, Xiuyu Cai, Qian Chu, Wenxian Wang, Qinhong Zhen, Yuefen Zhou, Wenfeng Li, Hong Pan, Hongsen Li, Tao Sun, Huanqing Cheng, Huina Wang, Feng Lou, Chuangzhou Rao, Shanbo Cao, Hongming Pan, Yong Fang
Anaplastic lymphoma kinase (ALK) fusions have been recognized as a therapeutic target in non-small cell lung cancer (NSCLC). However, molecular signatures and clinical characteristics of the Chinese population with ALK-rearranged NSCLC are not well elucidated. In the present study, we carried out targeted next-generation sequencing on tissue and plasma ctDNA samples in 1688 patients with NSCLC. Overall, ALK fusions were detected in 70 patients (4.1%), and the frequencies of ALK fusions detected in tissue and plasma samples were 5...
October 2019: Cancer Science